Jamison Private Wealth Management Inc. Acquires 784 Shares of GSK plc (NYSE:GSK)

Jamison Private Wealth Management Inc. grew its stake in GSK plc (NYSE:GSK) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,849 shares of the pharmaceutical company’s stock after acquiring an additional 784 shares during the period. Jamison Private Wealth Management Inc.’s holdings in GSK were worth $730,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of GSK. Register Financial Advisors LLC bought a new position in GSK in the first quarter valued at approximately $31,000. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK in the second quarter valued at $37,000. Richardson Financial Services Inc. bought a new stake in GSK during the fourth quarter worth $40,000. PrairieView Partners LLC acquired a new stake in GSK in the second quarter valued at $47,000. Finally, Triad Wealth Partners LLC bought a new position in shares of GSK in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research analyst reports. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group boosted their target price on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Finally, Citigroup raised shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

GSK opened at $38.96 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The business has a fifty day simple moving average of $41.50 and a 200 day simple moving average of $41.32. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a market capitalization of $80.74 billion, a PE ratio of 14.12, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. Research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were given a dividend of $0.3843 per share. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date of this dividend was Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is presently 55.80%.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.